(Updates shares, adds BofA commentary.)
- Truist analyst
Robyn Karnauskassays the broad approval -- including in mild-to-moderate as well as geriatric patients -- bodes well for the treatment in the larger dementia market
- She says the label warning on bradycardia and hypotension was not surprising and while the therapy has to be given by a health-care provider, “it looks like it can be given in multiple settings”
- BofA analyst ...